News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actinium Pharmaceuticals, Inc. (ATNM.OB) KOL Joseph Jurcic, MD To Discuss The Role Of Actinium’s Alpha-Particle Radiopharmaceuticals In The Treatment Of Leukemia Patients At The 2014 Society of Nuclear Medicine And Molecular Imaging Annual Meeting



6/5/2014 7:43:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium’s Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium’s alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES